Beam's Base-Edited Sickle Cell Therapy Meets Its Pivotal Endpoint, FDA Filing Possible by Year-End
- Beam said risto-cel, an autologous base-edited therapy that raises fetal hemoglobin, met the primary endpoint of the Phase 1/2 BEACON study: prevention of severe vaso-occlusive crises.
- The readout covers 31 patients with at least 12 months of follow-up; secondary goals, including fewer related hospitalizations, were also met, though detailed figures weren't released.
- Beam plans an FDA submission as soon as end-2026, which would be the first for a base-editing treatment.
💡 Points Based on public reports
This is the first positive late-stage base-editing readout, but the commercial question is the one Casgevy already faces: ex vivo editing needs conditioning and manufacturing capacity, and uptake has been slow. Risto-cel's edge has to come from tolerability and durability data we haven't seen yet, so the full dataset matters more than the headline. Investors sold on the news (shares fell up to 10%), a sign expectations were already high.
📰 Source · BioPharma Dive ↗ Beam's base editing therapy for sickle cell hits goal in pivotal trial